Cargando…

Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer

The locus at 17q12 erb‐b2 receptor tyrosine kinase 2 (ERBB2) has been heavily amplificated and overexpressed in gastric cancer (GC), but it remains to be elucidated about the clinical significance of the co‐amplification and co‐overexpression of PGAP3 gene located around ERBB2 in GC. The profile of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dong, Hao, Siyu, He, Hongjie, Zhang, Jian, You, Ge, Wu, Xin, Zhang, Rui, Meng, Xiangning, Cui, Xiaobo, Bai, Jing, Fu, Songbin, Yu, Jingcui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424286/
https://www.ncbi.nlm.nih.gov/pubmed/37386793
http://dx.doi.org/10.1111/jcmm.17828
_version_ 1785089641008857088
author Wang, Dong
Hao, Siyu
He, Hongjie
Zhang, Jian
You, Ge
Wu, Xin
Zhang, Rui
Meng, Xiangning
Cui, Xiaobo
Bai, Jing
Fu, Songbin
Yu, Jingcui
author_facet Wang, Dong
Hao, Siyu
He, Hongjie
Zhang, Jian
You, Ge
Wu, Xin
Zhang, Rui
Meng, Xiangning
Cui, Xiaobo
Bai, Jing
Fu, Songbin
Yu, Jingcui
author_sort Wang, Dong
collection PubMed
description The locus at 17q12 erb‐b2 receptor tyrosine kinase 2 (ERBB2) has been heavily amplificated and overexpressed in gastric cancer (GC), but it remains to be elucidated about the clinical significance of the co‐amplification and co‐overexpression of PGAP3 gene located around ERBB2 in GC. The profile of PGAP3 and ERBB2 in four GC cell lines and tissue microarrays containing 418 primary GC tissues was assessed to investigate the co‐overexpression and clinical significance of the co‐amplified genes, and to evaluate the impact of the co‐amplified genes on the malignancy of GC. Co‐amplification of PGAP3 and ERBB2 accompanied with co‐overexpression was observed in a haploid chromosome 17 of NCI‐N87 cells with double minutes (DMs). PGAP3 and ERBB2 were overexpressed and positively correlated in 418 GC patients. Co‐overexpression of the PGAP3 and ERBB2 was correlated with T stage, TNM stage, tumour size, intestinal histological type and poor survival proportion in 141 GC patients. In vitro, knockdown of the endogenous PGAP3 or ERBB2 decreased cell proliferation and invasion, increased G1 phase accumulation and induced apoptosis in NCI‐N87 cells. Furthermore, combined silencing of PGAP3 and ERBB2 showed an additive effect on resisting proliferation of NCI‐N87 cells compared with targeting ERBB2 or PGAP3 alone. Taken together, the co‐overexpression of PGAP3 and ERBB2 may be crucial due to its significant correlation with clinicopathological factors of GC. Haploid gain of PGAP3 co‐amplified with ERBB2 is sufficient to facilitate the malignancy and progression of GC cells in a synergistic way.
format Online
Article
Text
id pubmed-10424286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104242862023-08-15 Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer Wang, Dong Hao, Siyu He, Hongjie Zhang, Jian You, Ge Wu, Xin Zhang, Rui Meng, Xiangning Cui, Xiaobo Bai, Jing Fu, Songbin Yu, Jingcui J Cell Mol Med Original Articles The locus at 17q12 erb‐b2 receptor tyrosine kinase 2 (ERBB2) has been heavily amplificated and overexpressed in gastric cancer (GC), but it remains to be elucidated about the clinical significance of the co‐amplification and co‐overexpression of PGAP3 gene located around ERBB2 in GC. The profile of PGAP3 and ERBB2 in four GC cell lines and tissue microarrays containing 418 primary GC tissues was assessed to investigate the co‐overexpression and clinical significance of the co‐amplified genes, and to evaluate the impact of the co‐amplified genes on the malignancy of GC. Co‐amplification of PGAP3 and ERBB2 accompanied with co‐overexpression was observed in a haploid chromosome 17 of NCI‐N87 cells with double minutes (DMs). PGAP3 and ERBB2 were overexpressed and positively correlated in 418 GC patients. Co‐overexpression of the PGAP3 and ERBB2 was correlated with T stage, TNM stage, tumour size, intestinal histological type and poor survival proportion in 141 GC patients. In vitro, knockdown of the endogenous PGAP3 or ERBB2 decreased cell proliferation and invasion, increased G1 phase accumulation and induced apoptosis in NCI‐N87 cells. Furthermore, combined silencing of PGAP3 and ERBB2 showed an additive effect on resisting proliferation of NCI‐N87 cells compared with targeting ERBB2 or PGAP3 alone. Taken together, the co‐overexpression of PGAP3 and ERBB2 may be crucial due to its significant correlation with clinicopathological factors of GC. Haploid gain of PGAP3 co‐amplified with ERBB2 is sufficient to facilitate the malignancy and progression of GC cells in a synergistic way. John Wiley and Sons Inc. 2023-06-29 /pmc/articles/PMC10424286/ /pubmed/37386793 http://dx.doi.org/10.1111/jcmm.17828 Text en © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Wang, Dong
Hao, Siyu
He, Hongjie
Zhang, Jian
You, Ge
Wu, Xin
Zhang, Rui
Meng, Xiangning
Cui, Xiaobo
Bai, Jing
Fu, Songbin
Yu, Jingcui
Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title_full Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title_fullStr Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title_full_unstemmed Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title_short Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer
title_sort contribution of pgap3 co‐amplified and co‐overexpressed with erbb2 at 17q12 involved poor prognosis in gastric cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424286/
https://www.ncbi.nlm.nih.gov/pubmed/37386793
http://dx.doi.org/10.1111/jcmm.17828
work_keys_str_mv AT wangdong contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT haosiyu contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT hehongjie contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT zhangjian contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT youge contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT wuxin contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT zhangrui contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT mengxiangning contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT cuixiaobo contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT baijing contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT fusongbin contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer
AT yujingcui contributionofpgap3coamplifiedandcooverexpressedwitherbb2at17q12involvedpoorprognosisingastriccancer